Revagenix, Inc.
PrivateLast Round
Series B
Jan 5, 2024
Total Funding Raised
$10M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Revagenix, Inc. operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Series B round in January 2024.
Revagenix, Inc. is a biopharmaceutical company that discovers and develops precision-engineered anti-infective medicines for serious chronic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Revagenix, Inc. Comparables
Compare Revagenix, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Infex Therapeutics | 85% | |
| Vast Therapeutics | 81% | |
| Omnicin Therapeutics | 79% |
For institutional investors. Book with your work email.
Revagenix, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 5, 2024 | ||||
| Series A | Aug 3, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Revagenix, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| Novo Holdings | Series B |
| Tenmile | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 429% MoM, reaching 1.9K.
- Jul 26, 2026
Monthly visitors grew 58% MoM.
For institutional investors. Book with your work email.
Revagenix, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Revagenix, Inc.'s valuation, stock price, and market status.
Is Revagenix, Inc. a public or private company?
Revagenix, Inc. is a private company.
What is the current stock price of Revagenix, Inc.?
Revagenix, Inc. is a private company, so its shares have no public market price. Caplight tracks Revagenix, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Revagenix, Inc. worth (valuation)?
Valuation information for Revagenix, Inc. is not publicly available.
Can I buy Revagenix, Inc. stock?
Revagenix, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Revagenix, Inc.'s last funding round?
Revagenix, Inc.'s most recent funding round was Series B on January 5, 2024.
Who are the main investors in Revagenix, Inc.?
Key investors in Revagenix, Inc. include Tenmile.
Will Revagenix, Inc. IPO soon?
No public IPO plans have been announced for Revagenix, Inc..
How can I track Revagenix, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Revagenix, Inc.'s shares on secondary markets.